[go: up one dir, main page]

EP0250357A1 - 1- and/or 2-substituted ergoline derivatives - Google Patents

1- and/or 2-substituted ergoline derivatives Download PDF

Info

Publication number
EP0250357A1
EP0250357A1 EP19870730064 EP87730064A EP0250357A1 EP 0250357 A1 EP0250357 A1 EP 0250357A1 EP 19870730064 EP19870730064 EP 19870730064 EP 87730064 A EP87730064 A EP 87730064A EP 0250357 A1 EP0250357 A1 EP 0250357A1
Authority
EP
European Patent Office
Prior art keywords
ergolinyl
methyl
diethyl
urea
meaning
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP19870730064
Other languages
German (de)
French (fr)
Inventor
Gerhard Dr. Sauer
Bernd Schröter
Helmut Dr. Wachtel
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Bayer Pharma AG
Original Assignee
Schering AG
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Schering AG filed Critical Schering AG
Publication of EP0250357A1 publication Critical patent/EP0250357A1/en
Withdrawn legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D457/00—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid
    • C07D457/10—Heterocyclic compounds containing indolo [4, 3-f, g] quinoline ring systems, e.g. derivatives of ergoline, of the formula:, e.g. lysergic acid with hetero atoms directly attached in position 8
    • C07D457/12—Nitrogen atoms

Definitions

  • the invention relates to 1- and / or 2-substituted ergolinyl urea derivatives, their preparation and their use as medicaments.
  • the compounds according to the invention have the general formula I. wherein X represents a CH2-R2 group with R2 meaning a nucleophilic group and R1 is hydrogen, lower alkyl or X as defined above, and R3 is hydrogen or bromine and R6 is lower alkyl and C9 --- C10 is a CC single or CC double bond, and their acid addition salts.
  • R3 is a bromine atom, this is in the 12- or 13-position.
  • C9 represents a CC single bond, the hydrogen atom is in the ⁇ -position in the 10-position.
  • Lower alkyl radicals are understood to mean those having up to 6 carbon atoms, C 1-4 -alkyls being preferred, such as, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert. Butyl.
  • a nucleophilic group preferably means the following radicals: NR4R5, where R4 and R5 are each lower alkyl, OR7, where R7 is lower alkyl or acyl, SR8, where R8 is lower alkyl or optionally substituted aryl, CHR9COR10, where R9 is COCH3 or COO-lower alkyl and R10 represents hydrogen, lower alkyl or 0-lower alkyl, C ⁇ N or C ⁇ CH.
  • the aromatic can be substituted once or more in any position, for example with C 1-2 alkyl, C 1-2 alkoxy, halogen such as fluorine, chlorine, bromine or iodine.
  • Acyl preferably means acids with up to 4 carbon atoms, such as acetic acid, propionic acid, butyric acid and others.
  • the salts of the compounds of the formula I according to the invention are acid addition salts and are derived from customarily used acids.
  • Such acids are, for example, inorganic acids, such as, for example, hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid or phosphorous acid, or organic acids, such as, for example, aliphatic mono- or dicarboxylic acids, phenyl-substituted alkane carboxylic acids, hydroxyalkane carboxylic acids or alkene dicarboxylic acids or alkene dicarboxylic acids aliphatic or aromatic sulfonic acids.
  • Physiologically acceptable salts of these acids are therefore, for example, sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate , Isobutyrate, caproate, heptanoate, propiolate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, phthalate, methoxybenzoate, methoxybenzoate , Benzenesulfonate, to
  • the compounds of the formula I according to the invention are notable for a centrally antidopaminergic activity and / or ⁇ 2-receptor-blocking action.
  • the central dopamine receptor blockade was shown in an interaction test with the dopamine receptor agonist apomorphine in mice after a single i.p pretreatment (parameter: elimination of the hypothermia caused by apomorphine 5 mg / kg i.p.).
  • the central ⁇ 2-receptor blockade was shown in an interaction test with the ⁇ 2-receptor agonist clonidine from mice after a single ip pretreatment (parameter: elimination of the hypothermia caused by clonidine 0.1 mg / kg ip).
  • the compounds according to the invention can therefore be used as neuroleptics for the treatment of psychoses of the schizophrenic type or as antidepressants.
  • the compounds according to the invention are brought into the form of a pharmaceutical preparation which, in addition to the active ingredient, contains a pharmaceutical, organic or inorganic inert carrier material suitable for enteral or parental application, such as water, gelatin, gum arabic, milk sugar, starch , Magnesium stearate, talc, vegetable oils, polyalkylene glycols etc. contains.
  • a pharmaceutical, organic or inorganic inert carrier material suitable for enteral or parental application such as water, gelatin, gum arabic, milk sugar, starch , Magnesium stearate, talc, vegetable oils, polyalkylene glycols etc. contains.
  • the pharmaceutical preparations can be in solid form, for example as tablets, dragées, suppositories, capsules or in liquid form, for example as solutions, suspensions or emulsions. If necessary, they also contain auxiliary substances such as preservatives, stabilizers, wetting agents or emulsifiers, salts for changing the osmotic pressure or buffers
  • the compounds of general formula I according to the invention are prepared by methods known per se.
  • the process for the preparation of the compounds of the general formula I is characterized in that a compound of the general formula II wherein R3, R6 and C9 --- C10 have the meaning given above and R1 is hydrogen or lower alkyl, aminomethylated, if R1 is hydrogen, within 10 to 60 minutes to a compound with R1 in the meaning of CH2NR4R5, where R4 and R5 have the meaning given above and if desired converts this within 10 to 40 hours into a compound with X in the meaning of CH2NR4R5 and R1 in the meaning of CH2NR4R5, hydrogen or CH2OH, where R4 and R5 have the meaning given above and if R1 is lower Alkyl is to a compound with X in the meaning of CH2-NR4R5, where R4 and R5 have the meaning given above and, if desired, the compounds thus obtained are optionally nucleophilically substituted, after quaternization with methyl iodide, to give compounds with R2 in the abovementioned meaning and optionally then forms a
  • the aminomethylation takes place in a Mannich reaction with formaldehyde and secondary amine in the presence of an acid or directly with the Eschenmoser salt dimethyl methylene ammonium halide, for example iodide or chloride.
  • the kinetic product which is substituted in the 1-position is obtained after a reaction time of 10 to 60 minutes. After a reaction time of 10 to 40 hours in the presence of protons, this rearranges into the thermodynamically stable 2-substituted ergoline derivative.
  • the reaction temperature ranges from room temperature to 120 ° C.
  • R1 is hydrogen
  • compounds are obtained from 2-aminomethylated ergoline derivatives by further reaction with formaldehyde or secondary amine in the 1-position, in which R1 represents a CH2OH or a CH2NR4R5 group, in which R4 and R5 have the meaning given above.
  • Mineral acids such as HCl are among the acids. and organic acids such as acetic acid, propionic acid and others suitable.
  • the reaction can be carried out directly in the organic acid or in a polar protic or aprotic solvent such as dimethylacetamide, DMF N-methylpyrrolidone, dimethyl sulfoxide, acetonitrile, alcohols such as ethanol, methanol, propanol, chlorinated hydrocarbons such as methylene chloride and others.
  • a polar protic or aprotic solvent such as dimethylacetamide, DMF N-methylpyrrolidone, dimethyl sulfoxide, acetonitrile, alcohols such as ethanol, methanol, propanol, chlorinated hydrocarbons such as methylene chloride and others.
  • reaction mixture is worked up by the customary methods, for example by crystallization or chromatography.
  • the dialkylamino group can be exchanged nucleophilically directly or after prior quaternization.
  • the nitrogen atom of the aminomethylene group is first quaternized with methyl iodide in an inert solvent such as, for example, ethers such as diisopropyl ether, diethyl ether, tetrahydrofuran and others. with ice cooling to room temperature in 2 to 12 hours.
  • the nucleophilic exchange can be carried out with or without isolation of the quaternary ammonium salt.
  • the nucleophilic anion is used directly as a salt, for example as alkali salts such as potassium, lithium or sodium salt, or the anion is generated by other bases, for example with Hünig base, DABCO, DBU, alkali metal alcoholates, etc.
  • the reaction is carried out under ice cooling up to 50 ° C and is generally complete after 10 to 40 minutes.
  • inert solvents are suitable for nucleophilic substitution.
  • examples include: alcohols such as methanol, ethanol, propanol, butanol, isopropanol and others, chlorinated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride and others acyclic and cyclic ethers such as diisopropyl ether, diethyl ether, tetrahydrofuran, dioxane and others
  • Suitable nucleophilic anions are, for example: mercaptides, alcoholates, amines, nitriles, acetylenes, ⁇ -dicarbonyl compounds such as malonic esters, acetoacetic esters, acetylacetone and others. All of the reactions described above are expediently carried out under an inert gas atmosphere such as nitrogen or argon.
  • the compound obtained is dissolved in a little methanol and a concentrated solution of the desired organic acid in methanol is added at room temperature.
  • the Erfing also relates to the use of 2-substituted ergoline derivatives of the general formula I with X in the meaning of CH2-NR4R5 for the preparation of 2-methyl-ergoline derivatives of the general formula III where R6 has the meaning given above.
  • the compounds according to the invention are therefore intermediate products for the preparation of pharmacologically active compounds as described in EP-A 0160842.
  • the compounds of general formula III can be prepared, for example, by reacting the quaternary ammonium salt of the compounds of general formula I with X in the meaning of CH2NR4R5 and R1 and R3 in the meaning of hydrogen with sodium borohydride in polar solvents such as alcohols to 2 -Methyl-ergoline derivatives. The reaction is generally carried out at room temperature and is complete after about 30 hours.
  • the starting compounds are known or can be prepared by known methods.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)

Abstract

Compounds of the formula I <IMAGE> in which X represents a CH2-R<2> group with R<2> meaning a nucleophilic group and R<1> is hydrogen, lower alkyl or X having the abovementioned meaning, and R<3> is hydrogen or bromine and R<6> is lower alkyl and C9---C10 denotes a CC single or CC double bond, and their acid addition salts, their preparation and their use as medicaments.

Description

Die Erfindung betrifft 1-und/oder 2-substituierte Ergolinylharnstoffderivate, ihre Herstellung und ihre Verwendung als Arzneimittel.The invention relates to 1- and / or 2-substituted ergolinyl urea derivatives, their preparation and their use as medicaments.

Die erfindungsgemäßen Verbindungen haben die allgemeine Formel I

Figure imgb0001
worin
X eine CH₂-R²-Gruppe darstellt mit R² in der Bedeutung einer nucleo­philen Gruppe und
R¹ Wasserstoff, niederes Alkyl oder X in der obengenannten Bedeutung ist, und
R³ Wasserstoff oder Brom ist und
R⁶ niederes Alkyl ist und
C₉---C₁₀ eine CC-Einfach-oder CC-Doppelbindung bedeutet, sowie deren Säure additionssalze.The compounds according to the invention have the general formula I.
Figure imgb0001
 wherein
X represents a CH₂-R² group with R² meaning a nucleophilic group and
R1 is hydrogen, lower alkyl or X as defined above, and
R³ is hydrogen or bromine and
R⁶ is lower alkyl and
C₉ --- C₁₀ is a CC single or CC double bond, and their acid addition salts.

Bedeutet R³ ein Bromatom, so steht dieses in 12- oder 13-Stellung.If R³ is a bromine atom, this is in the 12- or 13-position.

Stellt C₉---C₁₀ eine CC-Einfachbindung dar, so steht das Wasserstoffatom in 10-Stellung α-ständig.C₉ --- C₁₀ represents a CC single bond, the hydrogen atom is in the α-position in the 10-position.

Unter niederen Alkylresten versteht man solche mit bis zu 6 Kohlenstoff­atomen, wobei C1-4-Alkyle bevorzugt sind wie zum Beispiel Methyl, Ethyl, n-Propyl, Isopropyl, n-Butyl, Isobutyl und tert. Butyl.Lower alkyl radicals are understood to mean those having up to 6 carbon atoms, C 1-4 -alkyls being preferred, such as, for example, methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl and tert. Butyl.

Unter einer nucleophilen Gruppe sind bevorzugt die folgenden Reste ge­meint: NR⁴R⁵, wobei R⁴ und R⁵ jeweils niederes Alkyl ist, OR⁷, wobei R⁷ niederes Alkyl oder Acyl ist, SR⁸, wobei R⁸ niederes Alkyl oder gegebenenfalls substituiertes Aryl ist, CHR⁹COR¹⁰, wobei R⁹ COCH₃ oder COO-nieder Alkyl bedeutet und R¹⁰ Wasser­stoff, nieder Alkyl oder 0-nieder Alkyl darstellt, C≡N oder C≡CH.
Der Aromat kann in jeder beliebigen Position ein- oder mehrfach substi­tuiert sein, beispielsweise mit C1-2-Alkyl, C1-2-Alkoxy, Halogen wie Fluor, Chlor, Brom oder Jod.A nucleophilic group preferably means the following radicals: NR⁴R⁵, where R⁴ and R⁵ are each lower alkyl, OR⁷, where R⁷ is lower alkyl or acyl, SR⁸, where R⁸ is lower alkyl or optionally substituted aryl, CHR⁹COR¹⁰, where R⁹ is COCH₃ or COO-lower alkyl and R¹⁰ represents hydrogen, lower alkyl or 0-lower alkyl, C≡N or C≡CH.
The aromatic can be substituted once or more in any position, for example with C 1-2 alkyl, C 1-2 alkoxy, halogen such as fluorine, chlorine, bromine or iodine.

Unter Acyl sind bevorzugt Säuren mit bis zu 4 Kohlenstoffatomen zu ver­stehen wie beispielsweise Essigsäure, Propionsäure, Buttersäure u.a..Acyl preferably means acids with up to 4 carbon atoms, such as acetic acid, propionic acid, butyric acid and others.

Die Salze der erfindungsgemäßen Verbindungen der Formel I sind Säureadditionssalze und leiten sich von üblicherweise verwendeten Säuren ab. Solche Säuren sind zum Beispiel anorganische Säuren, wie beispielsweise Chlorwasserstoffsäure, Salpetersäure, Phos­phorsäure, Schwefelsäure, Bromwasserstoffsäure, Jodwasserstoff­säure, salpetrige Säure oder phosphorige Säure, oder organische Säuren, wie beispielsweise aliphatische Mono- oder Dicarbon­säuren, phenylsubstituierte Alkancarbonsäuren, Hydroxyalkan­carbonsäuren oder Alkendicarbonsäuren, aromatische Säuren oder aliphatische oder aromatische Sulfonsäuren. Physiologisch unbe­denkliche Salze dieser Säuren sind daher z.B. das Sulfat, Pyro­sulfat, Bisulfat, Sulfit, Bisulfit, Nitrat, Phosphat, Monohydro­genphosphat, Dihydrogenphosphat, Metaphosphat, Pyrophosphat, Chlorid, Bromid, Jodid, Fluorid, Acetat, Propionat, Decanoat, Caprylat, Acrylat, Formiat, Isobutyrat, Caproat, Heptanoat, Propiolat, Malonat, Succinat, Suberat, Sebacat, Fumarat, Maleat, Mandelat, Butin-1.4-dioat, Hexin-1.6-dioat, Benzoat, Chlorbenzoat, Methylbenzoat, Dinitrobenzoat, Hydroxybenzoat, Methoxybenzoat, Phthalat, Terephthalat, Benzolsulfonat, Toluol­sulfonat, Chlorbenzolsulfonat, Xylolsulfonat, Phenylacetat, Phenylpropionat, Phenylbutyrat, Citrat, Lactat, β-Hydroxybutyrat, Glycollat, Malat, Tartrat, Methansulfonat, Propansulfonat, Naphthalin-1-sulfonat oder Naphthalin-2-sulfonat.The salts of the compounds of the formula I according to the invention are acid addition salts and are derived from customarily used acids. Such acids are, for example, inorganic acids, such as, for example, hydrochloric acid, nitric acid, phosphoric acid, sulfuric acid, hydrobromic acid, hydroiodic acid, nitrous acid or phosphorous acid, or organic acids, such as, for example, aliphatic mono- or dicarboxylic acids, phenyl-substituted alkane carboxylic acids, hydroxyalkane carboxylic acids or alkene dicarboxylic acids or alkene dicarboxylic acids aliphatic or aromatic sulfonic acids. Physiologically acceptable salts of these acids are therefore, for example, sulfate, pyrosulfate, bisulfate, sulfite, bisulfite, nitrate, phosphate, monohydrogenphosphate, dihydrogenphosphate, metaphosphate, pyrophosphate, chloride, bromide, iodide, fluoride, acetate, propionate, decanoate, caprylate, acrylate, formate , Isobutyrate, caproate, heptanoate, propiolate, malonate, succinate, suberate, sebacate, fumarate, maleate, mandelate, butyne-1,4-dioate, hexyne-1,6-dioate, benzoate, chlorobenzoate, methylbenzoate, dinitrobenzoate, hydroxybenzoate, phthalate, methoxybenzoate, methoxybenzoate , Benzenesulfonate, toluenesulfonate, chlorobenzenesulfonate, xylenesulfonate, phenylacetate, phenylpropionate, phenylbutyrate, citrate, lactate, β-hydroxybutyrate, glycolate, malate, tartrate, methanesulfonate, propanesulfonate, naphthalene-1-sulfonate-1-sulfonate.

Im Vergleich zu bekannten, in 2-Stellung nicht substituierten Ergolinen, wie zum Beispiel dem Lisurid oder dem Tergurid, zeichnen sich die er­findungsgemäßen Verbindungen der Formel I durch eine zentral antidopamin­erge Wirksamkeit und/oderα₂-rezeptorblockierende Wirkung aus.Compared to known ergolines which are not substituted in the 2-position, such as, for example, the lisuride or the terguride, the compounds of the formula I according to the invention are notable for a centrally antidopaminergic activity and / or α₂-receptor-blocking action.

Die zentrale Dopaminrezeptorblockade wurde in einem Interak­tionstest mit dem Dopaminrezeptoragonisten Apomorphin an Mäu­sen nach einmaliger i.p-Vorbehandlung dargestellt (Parameter: Aufhebung der durch Apomorphin 5 mg/kg i.p. verursachten Hypo­thermie). Männliche NMRI-Mäuse wurden mit verschiedenen Dosen der Substanz, die selbst nicht die Thermoregulation der Versuchs­tiere beeinflußen, bzw. mit Trägermedium vorbehandelt. 30 Mi­nuten später erhielten alle Tiere Apomorphin 5 mg/kg i.p. 60 Minuten nach Zugabe von Substanz bzw. Trägermedium (= 30 Minuten nach Apomorphin) wurde die Rektaltemperatur mit Hilfe einer Thermosonde gemessen. Während die mit Trägermedium vorbehandelten Mäuse eine Hypothermie aufwiesen, war an mit Substanz vorbehandelten Tieren der körpertemperatursenkende Effekt des Apomorphin dosisabhängig aufgehoben.The central dopamine receptor blockade was shown in an interaction test with the dopamine receptor agonist apomorphine in mice after a single i.p pretreatment (parameter: elimination of the hypothermia caused by apomorphine 5 mg / kg i.p.). Male NMRI mice were pretreated with various doses of the substance, which themselves do not influence the thermoregulation of the test animals, or with a carrier medium. 30 minutes later, all animals received apomorphine 5 mg / kg i.p. 60 minutes after the addition of substance or carrier medium (= 30 minutes after apomorphine), the rectal temperature was measured using a thermal probe. While the mice pretreated with the carrier medium showed hypothermia, the body temperature-lowering effect of the apomorphine was eliminated in a dose-dependent manner on animals pretreated with the substance.

Die zentrale α₂-Rezeptorblockade wurde in einem Interaktions­test mit demα₂-Rezeptoragonisten Clonidin aus Mäusen nach ein­maliger i.p.-Vorbehandlung dargestellt (Parameter: Aufhebung der durch Clonidin 0,1 mg/kg i.p. verursachten Hypothermie). Männliche NMRI-Mäuse wurden mit verschiedenen Dosen der Substanz, die selbst nicht die Thermoregulation der Versuchstiere beein­flussen. bzw. mit Trägermedium vorbehandelt. 30 Minuten später erhielten alle Tiere Clonidin 0,1 mg/kg i.p., 60 Minuten nach Zugabe von Substanz bzw. Trägermedium (=30 Minuten nach Clonidin) wurde die Rektaltemperatur mit Hilfe einer Thermosonde gemessen. Während die mit Trägermedium vorbehandelten Mäuse eine Hypothermie aufwiesen, war an mit Substanz vorbehandelten Tieren der körper­temperatursenkende Effekt des Clondidin dosisabhängig aufgehoben.The central α₂-receptor blockade was shown in an interaction test with the α₂-receptor agonist clonidine from mice after a single ip pretreatment (parameter: elimination of the hypothermia caused by clonidine 0.1 mg / kg ip). Male NMRI mice were given different doses of the substance, which themselves did not affect the thermoregulation of the test animals. or pretreated with carrier medium. 30 minutes later, all animals received clonidine 0.1 mg / kg ip, 60 minutes after the addition of substance or carrier medium (= 30 minutes after clonidine) the rectal temperature was measured using a thermal probe. While the mice pretreated with the carrier medium showed hypothermia, the body temperature-lowering effect of the clondidine on the animals pretreated with the substance was eliminated in a dose-dependent manner.

Aufgrund dieser Befunde können die erfindungsgemäßen Verbindungen daher als Neuroleptika zur Behandlung von Psychosen des schizophrenen Formen­kreises oder als Antidepressiva verwendet werden.On the basis of these findings, the compounds according to the invention can therefore be used as neuroleptics for the treatment of psychoses of the schizophrenic type or as antidepressants.

Zur Verwendung der erfindungsgemäßen Verbindungen als Arzneimittel werden diese in die Form eines pharmazeutischen Präparats gebracht, das neben dem Wirkstoff ein für die enterale oder parentale Applikation geeignete pharmazeutische, organische oder anorganische inerte Trägermaterialien, wie zum Beispiel Wasser, Gelatine, Gummi arabicum, Milchzucker, Stärke, Magnesiumstearat, Talk, pflanzliche Öle, Polyalkylenglykole usw. enthält. Die pharmazeutischen Präparate können in fester Form, zum Beispiel als Tabletten, Dragées, Suppositorien, Kapseln oder in flüssiger Form, zum Beispiel als Lösungen, Suspensionen oder Emulsionen vorliegen. Gegeben­enfalls enthalten sie darüberhinaus Hilfsstoffe wie Konservierungs,- Stabilisierungs-, Netzmittel oder Emulgatoren, Salze zur Veränderung des osmotischen Drucks oder Puffer.For the use of the compounds according to the invention as pharmaceuticals, they are brought into the form of a pharmaceutical preparation which, in addition to the active ingredient, contains a pharmaceutical, organic or inorganic inert carrier material suitable for enteral or parental application, such as water, gelatin, gum arabic, milk sugar, starch , Magnesium stearate, talc, vegetable oils, polyalkylene glycols etc. contains. The pharmaceutical preparations can be in solid form, for example as tablets, dragées, suppositories, capsules or in liquid form, for example as solutions, suspensions or emulsions. If necessary, they also contain auxiliary substances such as preservatives, stabilizers, wetting agents or emulsifiers, salts for changing the osmotic pressure or buffers.

Die Herstellung der erfindungsgemäßen Verbindungen der allgemeinen Formel I erfolgt nach an sich bekannten Methoden.The compounds of general formula I according to the invention are prepared by methods known per se.

Beispielsweise ist das Verfahren zur Herstellung der Verbindungen der all­gemeinen Formal I dadurch gekennzeichnet, daß man eine Verbindung der all­gemeinen Formel II

Figure imgb0002
worin
R³, R⁶ und C₉---C₁₀ die oben genannte Bedeutung haben und R¹ Wasserstoff oder niederes Alkyl darstellt, aminomethyliert, falls R¹ Wasserstoff ist, innerhalb von 10 bis 60 Minuten zu einer Verbindung mit R¹ in der Bedeutung von CH₂NR⁴R⁵, wobei R⁴ und R⁵ die oben genannte Bedeutung haben und gewünschtenfalls diese innerhalb von 10 bis 40 Stunden um­wandelt in eine Verbindung mit X in der Bedeutung von CH₂NR⁴R⁵ und R¹ in der Bedeutung von CH₂NR⁴R⁵ , Wasserstoff oder CH₂OH, wobei R⁴ und R⁵ die oben genannte Bedeutung haben und falls R¹ niederes Alkyl ist, zu einer Verbindung mit X in der Bedeutung von CH₂-NR⁴R⁵ , wobei R⁴ und R⁵ die oben genannte Bedeutung haben und gewünschtenfalls anschließend die so erhaltenen Verbindungen gegebenenfalls nach Quartärnisierung mit Methyliodid nucleophil substituiert zu Verbindungen mit R² in der oben genannten Bedeutung und gegebenenfalls anschließend ein physiologisch ver­trägliches Säureadditionssalz bildet.For example, the process for the preparation of the compounds of the general formula I is characterized in that a compound of the general formula II
Figure imgb0002
 wherein
R³, R⁶ and C₉ --- C₁₀ have the meaning given above and R¹ is hydrogen or lower alkyl, aminomethylated, if R¹ is hydrogen, within 10 to 60 minutes to a compound with R¹ in the meaning of CH₂NR⁴R⁵, where R⁴ and R⁵ have the meaning given above and if desired converts this within 10 to 40 hours into a compound with X in the meaning of CH₂NR⁴R⁵ and R¹ in the meaning of CH₂NR⁴R⁵, hydrogen or CH₂OH, where R⁴ and R⁵ have the meaning given above and if R¹ is lower Alkyl is to a compound with X in the meaning of CH₂-NR⁴R⁵, where R⁴ and R⁵ have the meaning given above and, if desired, the compounds thus obtained are optionally nucleophilically substituted, after quaternization with methyl iodide, to give compounds with R² in the abovementioned meaning and optionally then forms a physiologically acceptable acid addition salt.

Die Aminomethylierung erfolgt in einer Mannichreaktion mit Formaldehyd und sekundärem Amin in Gegenwart einer Säure oder direkt mit dem Eschenmoser-­Salz Dimethyl-methylen-ammonium-halogenid, beispielsweise Jodid oder Chlorid.The aminomethylation takes place in a Mannich reaction with formaldehyde and secondary amine in the presence of an acid or directly with the Eschenmoser salt dimethyl methylene ammonium halide, for example iodide or chloride.

Bei der Aminomethylierung erhält man nach einer Reaktionszeit von 10 bis 60 Minuten das kinetische Produkt, das in 1-Stellung substituiert ist. Dieses lagert sich nach einer Reaktionszeit von 10 bis 40 Stunden in Gegenwart von Protonen in das thermodynamisch stabile 2-substituierte Ergolinderivat um. Die Reaktionstemperatur geht von Raumtemperatur bis zu 120 °C.In the aminomethylation, the kinetic product which is substituted in the 1-position is obtained after a reaction time of 10 to 60 minutes. After a reaction time of 10 to 40 hours in the presence of protons, this rearranges into the thermodynamically stable 2-substituted ergoline derivative. The reaction temperature ranges from room temperature to 120 ° C.

Falls R¹ Wasserstoff ist, werden aus 2-aminomethylierten Ergolinderivaten durch nochmalige Reaktion mit Formaldehyd oder sekundärem Amin in 1-Stellung Verbindungen erhalten, in denen R¹ eine CH₂OH- oder eine CH₂NR⁴R⁵ -Gruppe darstellt, worin R⁴ und R⁵ die oben genannte Bedeutung haben.If R¹ is hydrogen, compounds are obtained from 2-aminomethylated ergoline derivatives by further reaction with formaldehyde or secondary amine in the 1-position, in which R¹ represents a CH₂OH or a CH₂NR⁴R⁵ group, in which R⁴ and R⁵ have the meaning given above.

Als Säuren sind Mineralsäuren wie HCl u.a. und organische Säuren wie Essigsäure, Propionsäure u.a. geeignet. Die Reaktion kann direkt in der organischen Säure oder in einem polaren protischen oder aprotischen Lösungsmittel durchgeführt werden wie beispielsweise Dimethylacetamid, DMF N-Methylpyrrolidon, Dimethylsulfoxid, Acetonitril, Alkoholen wie Ethanol, Methanol, Propanol, chlorierten Kohlenwasserstoffen wie Methylenchlorid u.a..Mineral acids such as HCl are among the acids. and organic acids such as acetic acid, propionic acid and others suitable. The reaction can be carried out directly in the organic acid or in a polar protic or aprotic solvent such as dimethylacetamide, DMF N-methylpyrrolidone, dimethyl sulfoxide, acetonitrile, alcohols such as ethanol, methanol, propanol, chlorinated hydrocarbons such as methylene chloride and others.

Die Aufarbeitung des Reaktionsgemisches erfolgt nach den üblichen Methoden wie beispielsweise durch Kristallisation oder Chromatographie.The reaction mixture is worked up by the customary methods, for example by crystallization or chromatography.

Mit oder ohne Isolierung der aminomethylierten Ergolinderivate kann die Dialkylaminogruppe direkt oder nach vorheriger Quartärnisierung nucleophil ausgetauscht werden. Zweckmäßigerweise quartärnisiert man zunächst das Stickstoffatom der Aminomethylengruppe mit Methyliodid in einem inerten Lösungsmittel wie beispielsweise Ethern wie Diisopropylether, Diethyl­ether, Tetrahydrofuran u.a. unter Eiskühlung bis Raumtemperatur in 2 bis 12 Stunden.With or without isolation of the aminomethylated ergoline derivatives, the dialkylamino group can be exchanged nucleophilically directly or after prior quaternization. Advantageously, the nitrogen atom of the aminomethylene group is first quaternized with methyl iodide in an inert solvent such as, for example, ethers such as diisopropyl ether, diethyl ether, tetrahydrofuran and others. with ice cooling to room temperature in 2 to 12 hours.

Der nucleophile Austausch kann mit oder ohne Isolierung des quartären Ammoniumsalzes vorgenommen werden.The nucleophilic exchange can be carried out with or without isolation of the quaternary ammonium salt.

Hierbei wird das nucleophile Anion direkt als Salz beispielsweise als Alkalisalze wie Kalium-, Lithium- oder Natriumsalz verwendet oder es wird durch andere Basen das Anion erzeugt beispielsweise mit Hünig Base, DABCO, DBU, Alkalialkoholate u.a..Here, the nucleophilic anion is used directly as a salt, for example as alkali salts such as potassium, lithium or sodium salt, or the anion is generated by other bases, for example with Hünig base, DABCO, DBU, alkali metal alcoholates, etc.

Die Reaktion wird unter Eiskühlung bis zu 50 °C durchgeführt und ist im allgemeinen nach 10 bis 40 Mintuen beendet.The reaction is carried out under ice cooling up to 50 ° C and is generally complete after 10 to 40 minutes.

Alle inerten Lösungsmittel sind für die nucleophile Substitution geeignet. Beispielsweise genannt seien: Alkohole wie Methanol, Ethanol, Propanol, Butanol, Isopropanol u.a., chlorierte Kohlenwasserstoffe wie Methylenchlorid, Chloroform, Tetrachlorkohlenstoff u.a. acyclische und cyclische Ether wie Diisopropylether, Diethylether, Tetrahydrofuran, Dioxan u.a. Als nucleophile Anionen sind beispielsweise geeignet: Mercaptide, Alko­holate, Amine, Nitrile, Acetylene, β-Dicarbonylverbindungen wie Malonester, Acetessigester, Acetylaceton u.a..
Alle oben beschriebenen Reaktionen werden zweckmäßigerweise unter Inert­gasatmosphäre wie Stickstoff oder Argon vorgenommen.All inert solvents are suitable for nucleophilic substitution. Examples include: alcohols such as methanol, ethanol, propanol, butanol, isopropanol and others, chlorinated hydrocarbons such as methylene chloride, chloroform, carbon tetrachloride and others acyclic and cyclic ethers such as diisopropyl ether, diethyl ether, tetrahydrofuran, dioxane and others Suitable nucleophilic anions are, for example: mercaptides, alcoholates, amines, nitriles, acetylenes, β-dicarbonyl compounds such as malonic esters, acetoacetic esters, acetylacetone and others.
All of the reactions described above are expediently carried out under an inert gas atmosphere such as nitrogen or argon.

Zur Bildung von Salzen wird die erhaltene Verbindung in wenig Methanol gelöst und mit einer konzentrierten Lösung der gewünschten organischen Säure in Methanol bei Raumtemperatur versetzt.To form salts, the compound obtained is dissolved in a little methanol and a concentrated solution of the desired organic acid in methanol is added at room temperature.

Die Erfing betrifft ferner die Verwendung von 2-substituierten Ergolin­derivaten der allgemeinen Formel I mit X in der Bedeutung von CH₂-NR⁴R⁵ zur Herstellung von 2-Methyl-ergolinderivaten der allgemeinen Formel III

Figure imgb0003
worin R⁶ die oben genannte Bedeutung hat. Die erfindungsgemäßen Ver­bindungen sind daher Zwischenprodukte zur Herstellung von pharmakologisch wirksamen Verbindungen wie sie in der EP-A 0160842 beschrieben sind.The Erfing also relates to the use of 2-substituted ergoline derivatives of the general formula I with X in the meaning of CH₂-NR⁴R⁵ for the preparation of 2-methyl-ergoline derivatives of the general formula III
Figure imgb0003
 where R⁶ has the meaning given above. The compounds according to the invention are therefore intermediate products for the preparation of pharmacologically active compounds as described in EP-A 0160842.

Die Verbindungen der allgemeinen Formel III kann man beispielsweise her­stellen, indem man das quartäre Ammo niumsalz der Verbindungen der all­gemeinen Formel I mit X in der Bedeutung von CH₂NR⁴R⁵ und R¹ und R³ in der Bedeutung von Wasserstoff mit Natriumborhydrid in polaren Lösungsmitteln wie beispielsweise Alkoholen umsetzt zu 2-Methyl-ergolin­derivaten. Die Reaktion wird im allgemeinen bei Raumtemperatur durchge­führt und ist nach circa 30 Stunden beendet.The compounds of general formula III can be prepared, for example, by reacting the quaternary ammonium salt of the compounds of general formula I with X in the meaning of CH₂NR⁴R⁵ and R¹ and R³ in the meaning of hydrogen with sodium borohydride in polar solvents such as alcohols to 2 -Methyl-ergoline derivatives. The reaction is generally carried out at room temperature and is complete after about 30 hours.

Die Ausgangsverbindungen sind bekannt oder können nach bekannten Methoden hergestellt werden.The starting compounds are known or can be prepared by known methods.

Die nachfolgenden Beispiele sollen das erfindungsgemäße Verfahren er­läutern.The following examples are intended to explain the process according to the invention.

Beispiel 1example 1 1,1-Diethyl-3-(1-dimethylaminomethyl-6-methyl-8α-ergolinyl)-harnstoff1,1-diethyl-3- (1-dimethylaminomethyl-6-methyl-8α-ergolinyl) urea

  • a) 340 mg Tergurid (1 mMol) löst man in 20 ml Dichlormethan und gibt 240 mg Dimethylmethylenammonium-iodid (1,3 mMol) fest zu. Nach 20 Stun­den Rühren bei Raumtemperatur unter Inertgas wird zwischen 1n NaOH und Dichlormethan verteilt, die organische Phase abgetrennt, mit Natrium­sulfat getrocknet und eingedampft. Der Rückstand wird an Kieselgel mit Dichlormethan und Methanol chromatographiert und aus Diisoprpylether kristallisiert, Ausbeute 232 mg (58 % d.Th.).
    [α]D = + 8 ° (0,5 % in Chloroform).    a) 340 mg of terguride (1 mmol) are dissolved in 20 ml of dichloromethane and 240 mg of dimethylmethylene ammonium iodide (1.3 mmol) are added in solid form. After stirring for 20 hours at room temperature under inert gas, the mixture is partitioned between 1N NaOH and dichloromethane, the organic phase is separated off, dried with sodium sulfate and evaporated. The residue is chromatographed on silica gel with dichloromethane and methanol and crystallized from diisopryl ether, yield 232 mg (58% of theory).
    [α] D = + 8 ° (0.5% in chloroform).
  • b) Man löst 3,4 g Tergurid in 72 ml Eisessig, gibt 120 ml 40 %ige Dimethyl­aminlösung und 58 ml 37 % Formaldehydlösung zu und erwärmt 30 Minuten auf 70 ° unter Argon. Die Mischung wird im Eisbad abgekühlt, mit konz. Ammoniak alkalisch gemacht und mit Essigester ausgeschüttelt, Die or­ganische Phase wird mit Natriumsulfat getrocknet, eingedampft und der Rückstand wie oben chromatographiert, Ausbeute 82 %.b) 3.4 g of terguride are dissolved in 72 ml of glacial acetic acid, 120 ml of 40% dimethylamine solution and 58 ml of 37% formaldehyde solution are added, and the mixture is heated to 70 ° under argon for 30 minutes. The mixture is cooled in an ice bath, with conc. Ammonia made alkaline and shaken with ethyl acetate, the organic phase is dried with sodium sulfate, evaporated and the residue is chromatographed as above, yield 82%.

1,1,-Diethyl-3-(1-diethylaminomethyl-6-methyl-8α-ergolinyl)-harnstoff dargestellt wie in vorstehendem Beispiel b)1,1, -Diethyl-3- (1-diethylaminomethyl-6-methyl-8α-ergolinyl) urea represented as in example b) above

Beispiel 2Example 2 1,1-Diethyl-3-(2-dimethylaminomethyl-6-methyl-8α-ergolinyl)-harnstoff1,1-diethyl-3- (2-dimethylaminomethyl-6-methyl-8α-ergolinyl) urea

Man löst 596 mg 1,1-Diethyl-3-(1-dimethylaminomethyl-6-methyl-8α-ergolinyl)-­harnstoff in 11 ml Eisessig, gibt noch 15 ml 40%ige Dimethylaminlösung und 7 ml 37 %ige Formaldehydlösung zu und rührt über Nacht bei 70 °. Dann wird wie oben beschrieben aufgearbeitet und chromatographiert, wobei man 147 mg isoliert, Aus Diisopropylether kristallisieren 113 mg der gewünschten Ver­bindung, (19 % d.Th.),
[α]D = + 14 ° (0,5 % in Chloroform)596 mg of 1,1-diethyl-3- (1-dimethylaminomethyl-6-methyl-8α-ergolinyl) urea are dissolved in 11 ml of glacial acetic acid, 15 ml of 40% dimethylamine solution and 7 ml of 37% formaldehyde solution are added and the mixture is stirred overnight at 70 °. The mixture is then worked up and chromatographed as described above, 147 mg being isolated. 113 mg of the desired compound crystallize from diisopropyl ether (19% of theory).
[α] D = + 14 ° (0.5% in chloroform)

1,1,Diethyl-3-(2-dimethylaminomethyl-1-hydroxymethyl-6-methyl-8α-ergolinyl)- harnstoff1,1, diethyl-3- (2-dimethylaminomethyl-1-hydroxymethyl-6-methyl-8α-ergolinyl) urea

Eine Fraktion der vorstehend beschriebenen Chromatographie liefert 122 mg, Ausbeute 19 %.A fraction of the chromatography described above gives 122 mg, 19% yield.

Beispiel 3Example 3 1,1-Diethyl-3-(2-diethylaminomethyl-6-methyl-8α-ergolinyl)-harnstoff1,1-diethyl-3- (2-diethylaminomethyl-6-methyl-8α-ergolinyl) urea

In 300 ml Dimethylformamid löst man 10,2 g Tergurid (30 mMol), 33 g Diethylaminhydrochlorid (0,3 Mol) und 7,2 g Paraformaldehyd (0,24 Mol). Man erhitzt 24 Stunden auf 100 ° unter Argon, läßt dann abkühlen und ver­dünnt mit 100 ml Wasser. Mit 100 ml 1n Natronlauge macht man alkalisch, sättigt die Lösung mit Kochsalz und schüttelt mit Essigester aus. Die organische Phase wird mit Natriumsulfat getrocknet, eingeengt und mehrmals mit Toluol zur Vertreibung des Diemthylformamids destilliert. Der Rückstand wird an Alox (Aktivitätsstufe III) mit Chloroform und Essigester chromato­graphiert. Von der gewünschten Verbindung werden 8,9 g erhalten (70 %), die aus Essigester kristallisiert werden, Ausbeute 7,1 g (55 % d.Th.)
[α]D = + 17 ° (0,5% in Chloroform).10.2 g of terguride (30 mmol), 33 g of diethylamine hydrochloride (0.3 mol) and 7.2 g of paraformaldehyde (0.24 mol) are dissolved in 300 ml of dimethylformamide. The mixture is heated to 100 ° under argon for 24 hours, then allowed to cool and diluted with 100 ml of water. With 100 ml of 1N sodium hydroxide solution, make alkaline, saturate the solution with sodium chloride and shake out with ethyl acetate. The organic phase is dried with sodium sulfate, concentrated and distilled several times with toluene to drive off the dimethylformamide. The residue is chromatographed on Alox (activity level III) with chloroform and ethyl acetate. 8.9 g of the desired compound are obtained (70%), which are crystallized from ethyl acetate, yield 7.1 g (55% of theory)
[α] D = + 17 ° (0.5% in chloroform).

Als Nebenprodukt wird aus der vorstehenden Chromatographie 3-(1,2-bis-­(diethylaminomethyl)-6-methyl-8α-ergolinyl)-1,1-diethyl-harnstoff gewonnen.As a by-product, 3- (1,2-bis- (diethylaminomethyl) -6-methyl-8α-ergolinyl) -1,1-diethylurea is obtained from the above chromatography.

Auf gleiche Weise werden die folgenden Mannichbasen dargestellt:
3-(13-Brom-2-diethylaminomethyl-6-methyl-8α-ergolinyl)-1,1-diehtyl-harnstoff Ausbeute 43 %, [α]D = - 5 ° (0,5 % in Chloroform).The following Mannich bases are represented in the same way:
3- (13-bromo-2-diethylaminomethyl-6-methyl-8α-ergolinyl) -1,1-diehylurea yield 43%, [α] D = -5 ° (0.5% in chloroform).

3-(9,10-Didehydro-2-diethylaminomethyl-6-methyl-8α-ergolinyl)-1,1-diethyl­harnstoff
Ausbeute 31 %3- (9,10-Didehydro-2-diethylaminomethyl-6-methyl-8α-ergolinyl) -1,1-diethylurea
Yield 31%

1,1-Diethyl-3-(2-diethylaminomethyl)-6-n-propyl-8α-ergolinyl)-harnstoff1,1-diethyl-3- (2-diethylaminomethyl) -6-n-propyl-8α-ergolinyl) urea

1,1-Diethyl-3-(2-diethylaminomethyl-1,6-dimethyl-8α-ergolinyl)-harnstoff1,1-diethyl-3- (2-diethylaminomethyl-1,6-dimethyl-8α-ergolinyl) urea

Beispiel 4Example 4 (8α-(3,3-Diethylureido)-6-methyl-2-ergolinyl)-diethyl-methyl-ammonium-iodid(8α- (3,3-Diethylureido) -6-methyl-2-ergolinyl) -diethyl-methyl-ammonium iodide

2,12 g 1,1 Diethyl-3-(2-diethylaminomethyl-6-methyl-8α-ergolinyl)-harnstoff (5 mMol) löst man in 100 ml Tetrahydrofuran, kühlt im Eisbad und gibt 2,0 ml Iodmethan zu. Man rührt über Nacht bei 3 °C unter Argon, gibt dann 100 ml Diisopropylether zu und filtriert die ausgeschiedenen Kristalle ab. Ausbeute 2,4 g (84 %).
Dieses Quartärsalz wurde ohne weitere Reinigung für die folgenden Umsetzun­gen verwendet.2.12 g of 1.1 diethyl-3- (2-diethylaminomethyl-6-methyl-8α-ergolinyl) urea (5 mmol) is dissolved in 100 ml of tetrahydrofuran, cooled in an ice bath and 2.0 ml of iodomethane are added. The mixture is stirred overnight at 3 ° C. under argon, then 100 ml of diisopropyl ether are added and the crystals which have separated out are filtered off. Yield 2.4 g (84%).
This quaternary salt was used for the following reactions without further purification.

Beispiel 5Example 5 1,1-Diethyl-3-(2-methoxymethyl-6-methyl-8α-ergolinyl)-harnstoff1,1-Diethyl-3- (2-methoxymethyl-6-methyl-8α-ergolinyl) urea

345 mg Natrium (15 mMol) werden bei Raumtemperatur unter Argon in 60 ml wasserfreiem Methanol gelöst. Man kühlt im Eisbad ab und gibt 1,7 g Quartärsalz (3 mMol) fest zu. Nach 30 Minuten Rühren bei Raumtemperatur gibt man gesättigte Natriumchloridlösung zu und schüttelt mit Dichlormethan aus. Die organische Phase wird mit Natriumsulfat getrocknet, eingedampft und an Kieselgel mit Dichlormethan und Methanol chromatographiert und aus Diisopropylether kristallisiert, Ausbeute 138 mg (12 %).
[α]D = 11 ° (0,5 % in Chloroform).345 mg of sodium (15 mmol) are dissolved in 60 ml of anhydrous methanol at room temperature under argon. The mixture is cooled in an ice bath and 1.7 g of quaternary salt (3 mmol) are added. After stirring for 30 minutes at room temperature, saturated sodium chloride solution is added and the mixture is shaken out with dichloromethane. The organic phase is dried with sodium sulfate, evaporated and chromatographed on silica gel with dichloromethane and methanol and crystallized from diisopropyl ether, yield 138 mg (12%).
[α] D = 11 ° (0.5% in chloroform).

In analoger Weise erhält man mit Natriummethylmercaptid 1,1-Diethyl-3-(6-methyl-2-methylthiomethyl-8α-ergolinyl)-harnstoffAnalogously, 1,1-diethyl-3- (6-methyl-2-methylthiomethyl-8α-ergolinyl) urea is obtained with sodium methyl mercaptide

Ausbeute nach Kristallisation aus Dichlormethan und Diisopropylether 12 %, [α]D = + 18 ° (0,5 % in Chloroform).Yield after crystallization from dichloromethane and diisopropyl ether 12%, [α] D = + 18 ° (0.5% in chloroform).

Mit Natriumphenylmercaptid 1,1-Diethyl-3-(6-methyl-2-phenylthiomethyl-8α-ergolinyl)-harnstoffWith sodium phenyl mercaptide 1,1-diethyl-3- (6-methyl-2-phenylthiomethyl-8α-ergolinyl) urea

Ausbeute nach Kristallisation aus Dichlormethan und Diisopropylether 5 %, [α]D = 0 ° (0,5 % in Chloroform).Yield after crystallization from dichloromethane and diisopropyl ether 5%, [α] D = 0 ° (0.5% in chloroform).

Mit dem Natriumsalz des Acetessigesters 2-Acetyl-3-(8α-(3,3-diethylureido)-6-methyl-2-ergolinyl)-propionsäure­ethylesterWith the sodium salt of the acetoacetic ester 2-acetyl-3- (8α- (3,3-diethylureido) -6-methyl-2-ergolinyl) -propionic acid ethyl ester

Ausbeute nach Kristallisation aus Diisopropylether 7 %,
[α]D = + 4 ° (0,5 % in Chloroform).Yield after crystallization from diisopropyl ether 7%,
[α] D = + 4 ° (0.5% in chloroform).

Beispiel 6Example 6 1,1-Diethyl-3-(2,6-dimethyl-8α-ergolinyl)-harnstoff1,1-diethyl-3- (2,6-dimethyl-8α-ergolinyl) urea

0,8 g Natriumborhydrid (21 mMol) werden in 100 ml Ethanol gelöst. Dazu gibt man unter Argon 2,4 g Quartärsalz fest zu und rührt 23 Stunden bei Raumtem­peratur. Zur Vervollständigung der Reaktion werden weitere 0,2 g Natrium­borhydrid zugegeben und weitere 7 Stunden gerührt. Man versetzt mit 100 ml Wasser und 100 ml gesättigter Kochsalzlösung, rührt unter Eiskühlung und saugt die Kristalle ab, Ausbeute 0,92 g (52 %),
[α]D = + 12 ° (0,5 % in Chloroform).0.8 g sodium borohydride (21 mmol) are dissolved in 100 ml ethanol. 2.4 g of quaternary salt are added under argon and stirred for 23 hours at room temperature. To complete the reaction, a further 0.2 g of sodium borohydride are added and the mixture is stirred for a further 7 hours. 100 ml of water and 100 ml of saturated sodium chloride solution are added, the mixture is stirred with ice cooling and the crystals are filtered off with suction, yield 0.92 g (52%),
[α] D = + 12 ° (0.5% in chloroform).

Claims (5)

1.) Verbindungen der allgemeinen Formel I
Figure imgb0004
 worin
X eine CH₂-R²-Gruppe darstellt mit R² in der Bedeutung einer nucleo­philen Gruppe und
R¹ Wasserstoff, niederes Alkyl oder X in der obengenannten Bedeutung ist, und
R³ Wasserstoff oder Brom ist und
R⁶ niederes Alkyl ist und
C₉---C₁₀ eine CC-Einfach-oder CC-Doppelbindung bedeutet, sowie deren Säure additionssalze.1.) Compounds of the general formula I
Figure imgb0004
 wherein
X represents a CH₂-R² group with R² meaning a nucleophilic group and
R1 is hydrogen, lower alkyl or X as defined above, and
R³ is hydrogen or bromine and
R⁶ is lower alkyl and
C₉ --- C₁₀ is a CC single or CC double bond, and their acid addition salts. 2.) 1,1-Diethyl-3-(1-dimethylaminomethyl-6-methyl-8α-ergolinyl)-harnstoff
1,1-Diethyl-3-(1-diethylaminomethyl-6-methyl-8α-ergolinyl)-harnstoff
1,1-Diethyl-3-(2-dimethylaminomethyl-6-methyl-8α-ergolinyl)-harnstoff
1,1-Diethyl-3-(2-dimethylaminomethyl-1-hydroxymethyl-6-methyl-8α-­ergolinyl)-harnstoff
1,1-Diethyl-3-(2-diethylaminomethyl-6-methyl-8α-ergolinyl)-harnstoff
3-(1,2-bis-(diethylaminomethyl)-6-methyl-8α-ergolinyl)-1,1-diethyl-­harnstoff
3-(13-Brom-2-diethylaminomethyl-6-methyl-8α-ergolinyl)-1,1diethyl-­harnstoff
3-(9,10-Didehydro-2-diethylaminomethyl-6-methyl-8α-ergolinyl)-1,1-­diethyl-harnstoff
1,1-Diethyl-3-(2-diethylaminomethyl)-6-n-propyl-8α-ergolinyl)-­harnstoff
1,1-Diethyl-3-(2-diethylaminomethyl-1,6-dimethyl-8α-ergolinyl)-­harnstoff
1,1-Diethyl-3-(2-methoxymethyl-6-methyl-8α-ergolinyl)-harnstoff
1,1-Diethyl-3-(6-methyl-2-methylthiomethyl-8α-ergolinyl)-harnstoff
1,1-Diethyl-3-(6-methyl-2-phenylthiomethyl-8α-ergolinyl)-harnstoff
2-Acetyl-3-(8α-(3,3-diethylureido)-6-methyl-2-ergolinyl)-propion­säure-ethylester2.) 1,1-Diethyl-3- (1-dimethylaminomethyl-6-methyl-8α-ergolinyl) urea
1,1-diethyl-3- (1-diethylaminomethyl-6-methyl-8α-ergolinyl) urea
1,1-diethyl-3- (2-dimethylaminomethyl-6-methyl-8α-ergolinyl) urea
1,1-Diethyl-3- (2-dimethylaminomethyl-1-hydroxymethyl-6-methyl-8α-ergolinyl) urea
1,1-diethyl-3- (2-diethylaminomethyl-6-methyl-8α-ergolinyl) urea
3- (1,2-bis- (diethylaminomethyl) -6-methyl-8α-ergolinyl) -1,1-diethylurea
3- (13-bromo-2-diethylaminomethyl-6-methyl-8α-ergolinyl) -1,1-diethyl-urea
3- (9,10-Didehydro-2-diethylaminomethyl-6-methyl-8α-ergolinyl) -1,1-diethylurea
1,1-diethyl-3- (2-diethylaminomethyl) -6-n-propyl-8α-ergolinyl) urea
1,1-diethyl-3- (2-diethylaminomethyl-1,6-dimethyl-8α-ergolinyl) urea
1,1-Diethyl-3- (2-methoxymethyl-6-methyl-8α-ergolinyl) urea
1,1-diethyl-3- (6-methyl-2-methylthiomethyl-8α-ergolinyl) urea
1,1-Diethyl-3- (6-methyl-2-phenylthiomethyl-8α-ergolinyl) urea
2-Acetyl-3- (8α- (3,3-diethylureido) -6-methyl-2-ergolinyl) propionic acid ethyl ester 3.) Verfahren zur Herstellung der Verbindungen der allgemeinen Formel I dadurch gekennzeichnet, daß man eine Verbindung der allgemeinen Formel II
Figure imgb0005
 worin
R³, R⁶ und C₉---C₁₀ die oben genannte Bedeutung haben und R¹ Wasserstoff oder niederes Alkyl darstellt, aminomethyliert, falls R¹ Wasserstoff ist, innerhalb von 10 bis 60 Minuten zu einer Verbindung mit R¹ in der Bedeutung von CH₂NR⁴R⁵ , wobei R⁴ und R⁵ die oben genannte Bedeutung haben und gewünschtenfalls diese innerhalb von 10 bis 40 Stunden um­wandelt in eine Verbindung mit X in der Bedeutung von CH₂NR⁴R⁵ und R¹ in der Bedeutung von CH₂NR⁴R⁵ , Wasserstoff oder CH₂OH, wobei R⁴ und R⁵ die oben genannte Bedeutung haben und falls R¹ niederes Alkyl ist, zu einer Verbindung mit X in der Bedeutung von CH₂-NR⁴R⁵ , wobei R⁴ und R⁵ die oben genannte Bedeutung haben und gewünschtenfalls anschließend die so erhaltenen Verbindungen gegebenenfalls nach Quartärnisierung mit Methyliodid nucleophil substituiert zu Verbindungen mit R² in der oben genannten Bedeutung und gegebenenfalls anschließend ein physiologisch ver­trägliches Säureadditionssalz bildet.3.) Process for the preparation of the compounds of general formula I, characterized in that a compound of general formula II
Figure imgb0005
 wherein
R³, R⁶ and C₉ --- C₁₀ have the meaning given above and R¹ is hydrogen or lower alkyl, aminomethylated, if R¹ is hydrogen, within 10 to 60 minutes to a compound with R¹ in the meaning of CH₂NR⁴R⁵, where R⁴ and R⁵ have the meaning given above and if desired converts this within 10 to 40 hours into a compound with X in the meaning of CH₂NR⁴R⁵ and R¹ in the meaning of CH₂NR⁴R⁵, hydrogen or CH₂OH, where R⁴ and R⁵ have the meaning given above and if R¹ is lower Alkyl is to a compound with X in the meaning of CH₂-NR⁴R⁵, where R⁴ and R⁵ have the meaning given above and, if desired, the compounds thus obtained are optionally nucleophilically substituted, after quaternization with methyl iodide, to give compounds with R² in the abovementioned meaning and optionally then forms a physiologically acceptable acid addition salt. 4.) Verwendung der Verbindungen der allgemeinen Formel I zur Herstellung von Arzneimitteln.4.) Use of the compounds of general formula I for the manufacture of medicaments. 5.) Verwendung der Verbindungen der allgemeinen Formel Ia
Figure imgb0006
 worin R⁴, R⁵ und R⁶ die oben genannte Bedeutung haben zur Herstellung von Verbindungen der allgemeinen Formel III
Figure imgb0007
 worin R⁶ die oben genannte Bedeutung hat.5.) Use of the compounds of general formula Ia
Figure imgb0006
 wherein R⁴, R⁵ and R⁶ have the meaning given above for the preparation of compounds of general formula III
Figure imgb0007
 where R⁶ has the meaning given above.
EP19870730064 1986-06-16 1987-06-12 1- and/or 2-substituted ergoline derivatives Withdrawn EP0250357A1 (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
DE19863620293 DE3620293A1 (en) 1986-06-16 1986-06-16 1 AND / OR 2 SUBSTITUTED ERGOL DERIVATIVES
DE3620293 1986-06-16

Publications (1)

Publication Number Publication Date
EP0250357A1 true EP0250357A1 (en) 1987-12-23

Family

ID=6303147

Family Applications (1)

Application Number Title Priority Date Filing Date
EP19870730064 Withdrawn EP0250357A1 (en) 1986-06-16 1987-06-12 1- and/or 2-substituted ergoline derivatives

Country Status (2)

Country Link
EP (1) EP0250357A1 (en)
DE (1) DE3620293A1 (en)

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02142790A (en) * 1988-07-15 1990-05-31 Schering Ag 2-substituted ergoline, medicine with central-dopaminergic action containing same, and method and intermediate material for manufacturing said medicine
WO1990013550A1 (en) * 1989-05-12 1990-11-15 Schering Aktiengesellschaft 8α-ACYLAMINO-ERGOLINES, THEIR PREPARATION AND USE AS DRUGS
EP2067780A1 (en) * 2007-12-07 2009-06-10 Axxonis Pharma AG Ergoline derivatives as selective radical scavengers for neurons
EP4423084A4 (en) * 2021-10-26 2025-12-10 Diamond Therapeutics Inc ERGOLIN-DERIVED 5-HT2A RECEPTOR AGENTS

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3824661A1 (en) * 1988-07-15 1990-02-08 Schering Ag 2-Substituted 3-(8 alpha -ergolinyl)-1,1-diethylureas or -thioureas, their preparation and use as intermediates and in medicaments
PT628042E (en) * 1992-12-24 2002-01-30 Pharmacia & Upjohn Spa SEROTONINERGIC ERGOLINE DERIVATIVES

Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH394224A (en) * 1961-11-10 1965-06-30 Sandoz Ag Process for the preparation of derivatives of the 6-methyl-ergolen and -ergoline series which are substituted on the indole nitrogen atom
DE2335750A1 (en) * 1972-07-21 1974-02-14 Lilly Co Eli D-6-METHYL-2,8-DISUBST.-ERGOLINE
DE3308719A1 (en) * 1982-03-12 1983-09-22 SPOFA spojené podniky pro zdravotnickou v&yacute;robu, 13000 Praha 1-SUBSTITUTED N- (8 (ALPHA) -ERGOLINYL) -N'.N'-DIETHYL UREAS, THEIR PRODUCTION AND PHARMACOLOGICAL USE
EP0160842A2 (en) * 1984-04-09 1985-11-13 Schering Aktiengesellschaft 2-Substituted ergoline derivatives, processes for their preparation, and their use as medicaments
EP0217736A2 (en) * 1985-10-04 1987-04-08 Schering Aktiengesellschaft 1,2-Disubstituted ergoline derivatives

Patent Citations (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CH394224A (en) * 1961-11-10 1965-06-30 Sandoz Ag Process for the preparation of derivatives of the 6-methyl-ergolen and -ergoline series which are substituted on the indole nitrogen atom
DE2335750A1 (en) * 1972-07-21 1974-02-14 Lilly Co Eli D-6-METHYL-2,8-DISUBST.-ERGOLINE
DE3308719A1 (en) * 1982-03-12 1983-09-22 SPOFA spojené podniky pro zdravotnickou v&yacute;robu, 13000 Praha 1-SUBSTITUTED N- (8 (ALPHA) -ERGOLINYL) -N'.N'-DIETHYL UREAS, THEIR PRODUCTION AND PHARMACOLOGICAL USE
EP0160842A2 (en) * 1984-04-09 1985-11-13 Schering Aktiengesellschaft 2-Substituted ergoline derivatives, processes for their preparation, and their use as medicaments
EP0217736A2 (en) * 1985-10-04 1987-04-08 Schering Aktiengesellschaft 1,2-Disubstituted ergoline derivatives

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
HOUBEN WEYL "Methoden der organischen Chemie" 4. Auflage, Band 11/1, 1957, Georg Thieme Verlag, Stuttgart R. SCHROTER "Amine durch Kondensation" Seiten 778-780, 785-793 * Seiten 778-780, 788-790, 793 * *
HOUBEN!WEYL "Methoden der organischen Chemie" 4. Auflage, Band 11/2, 1958, Georg Thieme Verlag, Stuttgart F. MULLER "Eliminierung der Aminogruppe" Seiten 209-221 * Seiten 210-213, 220 * *

Cited By (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPH02142790A (en) * 1988-07-15 1990-05-31 Schering Ag 2-substituted ergoline, medicine with central-dopaminergic action containing same, and method and intermediate material for manufacturing said medicine
EP0351352A3 (en) * 1988-07-15 1991-07-03 Schering Aktiengesellschaft 2-substituted ergolines, their preparation and use
US5037832A (en) * 1988-07-15 1991-08-06 Schering Aktiengesellschaft 2-substituted ergolines
US5158957A (en) * 1988-07-15 1992-10-27 Schering Aktiengesellschaft 2-substituted ergolines
WO1990013550A1 (en) * 1989-05-12 1990-11-15 Schering Aktiengesellschaft 8α-ACYLAMINO-ERGOLINES, THEIR PREPARATION AND USE AS DRUGS
US5547958A (en) * 1989-05-12 1996-08-20 Schering Aktiengesellschaft N-(8α-ergolinyl)-amides
EP2067780A1 (en) * 2007-12-07 2009-06-10 Axxonis Pharma AG Ergoline derivatives as selective radical scavengers for neurons
WO2009071607A3 (en) * 2007-12-07 2009-09-24 Axxonis Pharma Ag Ergoline derivatives as selective radical scavengers for neurons
EP4423084A4 (en) * 2021-10-26 2025-12-10 Diamond Therapeutics Inc ERGOLIN-DERIVED 5-HT2A RECEPTOR AGENTS

Also Published As

Publication number Publication date
DE3620293A1 (en) 1987-12-17

Similar Documents

Publication Publication Date Title
DE69908546T2 (en) Imidazopyridine derivatives and process for their preparation
EP0160842B1 (en) 2-Substituted ergoline derivatives, processes for their preparation, and their use as medicaments
DE3151912A1 (en) NEW ERGOLIN AMINO DERIVATIVES, METHOD FOR THE PRODUCTION THEREOF AND THEIR USE AS MEDICINAL PRODUCTS
DE68912704T2 (en) Imidazole compound and process for its preparation.
EP0351352B1 (en) 2-Substituted ergolines, their preparation and use
EP0217736B1 (en) 1,2-disubstituted ergoline derivatives
EP0118848A2 (en) Ergoline derivatives, process for their preparation and their pharmaceutical application
DE68915310T2 (en) Process for the preparation of enantiomeric homogeneous aminopyrrolidinyl-naphthyridine and quinolonecarboxylic acids.
EP0250357A1 (en) 1- and/or 2-substituted ergoline derivatives
EP0217734B1 (en) 12- or 13-bromoergoline derivatives
DE3135305C2 (en) Process for the production of 8-ergolinyl ureas
DE3413657A1 (en) Novel ergolines
DE2459629C3 (en) Pyrimidinoaminoethylergoline derivatives, process for their preparation and pharmaceutical agent
WO1993001185A1 (en) 2,14-disubstituted ergolines, their production and use in medicaments
DE2841644C2 (en)
DE2554000A1 (en) 6-METHYL-8 (SUBSTITUTED) METHYLER GOLIN
DE2804263C3 (en) Process for the preparation of indoline derivatives
EP0220129A2 (en) 12- and 13-substituted ergoline derivatives
EP0217735A2 (en) 2-Substituted ergoline derivatives
EP0213062B1 (en) 1-alkylergolinylthiourea derivatives
EP0006451B1 (en) Imidazo (1,2-a) imidazoles, their acid addition salts, medicaments containing them and process for their preparation
DE3413659A1 (en) Novel 2-substituted ergoline derivatives
EP0252873A1 (en) 1-Aryl-ergolinyl urea derivatives, process for their preparation as well as the use of these compounds as medicaments
EP0351351A2 (en) 2&#39;-,12&#39;- or 13&#39;-Substituted 3-(8&#39;-alpha-ergolinyl)-1,1-diethyl urea, their preparation and use in medicines
DE2728870C2 (en) Process for the production of D-penicillamine and its salts

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 19870629

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): CH DE FR GB IT LI

17Q First examination report despatched

Effective date: 19900402

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION HAS BEEN WITHDRAWN

18W Application withdrawn

Withdrawal date: 19910320

R18W Application withdrawn (corrected)

Effective date: 19910320

RIN1 Information on inventor provided before grant (corrected)

Inventor name: WACHTEL, HELMUT, DR.

Inventor name: SCHROETER, BERND

Inventor name: SAUER, GERHARD, DR.